table of content
1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product Introduction
1.2 Global Urological Cancer Therapeutics Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Urological Cancer Therapeutics Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume for the Year 2017-2028
1.3 United States Urological Cancer Therapeutics Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Urological Cancer Therapeutics Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Urological Cancer Therapeutics Drugs Sales in Volume for the Year 2017-2028
1.4 Urological Cancer Therapeutics Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Urological Cancer Therapeutics Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Urological Cancer Therapeutics Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Urological Cancer Therapeutics Drugs Market Dynamics
1.5.1 Urological Cancer Therapeutics Drugs Industry Trends
1.5.2 Urological Cancer Therapeutics Drugs Market Drivers
1.5.3 Urological Cancer Therapeutics Drugs Market Challenges
1.5.4 Urological Cancer Therapeutics Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Urological Cancer Therapeutics Drugs Market Segment by Type
2.1.1 Xofigo (radium Ra 223 dichloride)
2.1.2 Jevtana (cabazitaxel)
2.1.3 Inlyta (axitinib)
2.1.4 Votrient (pazopanib hydrochloride)
2.1.5 Sutent (sunitinib malate)
2.1.6 Zytiga (abiraterone acetate)
2.1.7 Xtandi (enzalutamide)
2.1.8 Opdivo (nivolumab)
2.1.9 Provenge (sipuleucel-T)
2.2 Global Urological Cancer Therapeutics Drugs Market Size by Type
2.2.1 Global Urological Cancer Therapeutics Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Urological Cancer Therapeutics Drugs Market Size by Type
2.3.1 United States Urological Cancer Therapeutics Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Urological Cancer Therapeutics Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Urological Cancer Therapeutics Drugs Market Segment by Application
3.1.1 Hospital
3.1.2 Medical Research Laboratory
3.1.3 Others
3.2 Global Urological Cancer Therapeutics Drugs Market Size by Application
3.2.1 Global Urological Cancer Therapeutics Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Urological Cancer Therapeutics Drugs Market Size by Application
3.3.1 United States Urological Cancer Therapeutics Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Urological Cancer Therapeutics Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Urological Cancer Therapeutics Drugs Competitor Landscape by Company
4.1 Global Urological Cancer Therapeutics Drugs Market Size by Company
4.1.1 Top Global Urological Cancer Therapeutics Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Urological Cancer Therapeutics Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2017-2022)
4.2 Global Urological Cancer Therapeutics Drugs Concentration Ratio (CR)
4.2.1 Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Urological Cancer Therapeutics Drugs in 2021
4.2.3 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Urological Cancer Therapeutics Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Urological Cancer Therapeutics Drugs Market Size by Company
4.5.1 Top Urological Cancer Therapeutics Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Urological Cancer Therapeutics Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Urological Cancer Therapeutics Drugs Sales by Players (2020, 2021 & 2022)
5 Global Urological Cancer Therapeutics Drugs Market Size by Region
5.1 Global Urological Cancer Therapeutics Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Urological Cancer Therapeutics Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Urological Cancer Therapeutics Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Urological Cancer Therapeutics Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Urological Cancer Therapeutics Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Urological Cancer Therapeutics Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
7.1.5 Novartis Recent Development
7.2 Pfizer
7.2.1 Pfizer Corporation Information
7.2.2 Pfizer Description and Business Overview
7.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
7.2.5 Pfizer Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Corporation Information
7.3.2 Johnson & Johnson Description and Business Overview
7.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
7.3.5 Johnson & Johnson Recent Development
7.4 AstraZeneca
7.4.1 AstraZeneca Corporation Information
7.4.2 AstraZeneca Description and Business Overview
7.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
7.4.5 AstraZeneca Recent Development
7.5 Astellas
7.5.1 Astellas Corporation Information
7.5.2 Astellas Description and Business Overview
7.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
7.5.5 Astellas Recent Development
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporation Information
7.6.2 Bristol-Myers Squibb Description and Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
7.6.5 Bristol-Myers Squibb Recent Development
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Corporation Information
7.7.2 Abbott Laboratories Description and Business Overview
7.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
7.7.5 Abbott Laboratories Recent Development
7.8 Celgene Corporation
7.8.1 Celgene Corporation Corporation Information
7.8.2 Celgene Corporation Description and Business Overview
7.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
7.8.5 Celgene Corporation Recent Development
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Corporation Information
7.9.2 Dendreon Corporation Description and Business Overview
7.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
7.9.5 Dendreon Corporation Recent Development
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Corporation Information
7.10.2 Ferring Pharmaceuticals Description and Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
7.10.5 Ferring Pharmaceuticals Recent Development
7.11 GlaxoSmithKline plc
7.11.1 GlaxoSmithKline plc Corporation Information
7.11.2 GlaxoSmithKline plc Description and Business Overview
7.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products Offered
7.11.5 GlaxoSmithKline plc Recent Development
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Corporation Information
7.12.2 Indevus Pharmaceuticals Inc Description and Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Indevus Pharmaceuticals Inc Products Offered
7.12.5 Indevus Pharmaceuticals Inc Recent Development
7.13 Ipsen
7.13.1 Ipsen Corporation Information
7.13.2 Ipsen Description and Business Overview
7.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Ipsen Products Offered
7.13.5 Ipsen Recent Development
7.14 Roche Healthcare
7.14.1 Roche Healthcare Corporation Information
7.14.2 Roche Healthcare Description and Business Overview
7.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Roche Healthcare Products Offered
7.14.5 Roche Healthcare Recent Development
7.15 Sanofi S.A.
7.15.1 Sanofi S.A. Corporation Information
7.15.2 Sanofi S.A. Description and Business Overview
7.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Sanofi S.A. Products Offered
7.15.5 Sanofi S.A. Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Urological Cancer Therapeutics Drugs Industry Chain Analysis
8.2 Urological Cancer Therapeutics Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Urological Cancer Therapeutics Drugs Distributors
8.3 Urological Cancer Therapeutics Drugs Production Mode & Process
8.4 Urological Cancer Therapeutics Drugs Sales and Marketing
8.4.1 Urological Cancer Therapeutics Drugs Sales Channels
8.4.2 Urological Cancer Therapeutics Drugs Distributors
8.5 Urological Cancer Therapeutics Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
